@article{034e890ac93848cab494c7818bf2f72c,
title = "Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study",
abstract = "Background: Recurrent head and neck cancer has poor prognosis. Stereotactic body radiotherapy (SBRT) may improve outcomes by delivering ablative radiation doses. Methods: We reviewed patients who received definitive-intent SBRT reirradiation at our institution from 2013 to 2020. Patterns of failure, overall survival (OS), and toxicities were analyzed. Results: One hundred and thirty-seven patients were evaluated. The median OS was 44.3 months. The median SBRT dose was 45 Gy and median target volume 16.9 cc. The 1-year local, regional, and distant control was 78%, 66%, and 83%, respectively. Systemic therapy improved regional (p = 0.004) and distant control (p = 0.04) in nonmetastatic patients. Grade 3+ toxicities were more common at mucosal sites (p = 0.001) and with concurrent systemic therapy (p = 0.02). Conclusions: In a large cohort of SBRT reirradiation for recurrent, small volume head and neck cancers, a median OS of 44.3 months was observed. Systemic therapy improved regional and distant control. Toxicities were modulated by anatomic site and systemic therapy.",
keywords = "head and neck neoplasms, recurrence, reirradiation, salvage therapy, stereotactic body radiotherapy",
author = "Kevin Diao and Nguyen, {Theresa P.} and Moreno, {Amy C.} and Reddy, {Jay P.} and Garden, {Adam S.} and Wang, {Catherine H.} and Samuel Tung and Congjun Wang and Wang, {Xin A.} and Rosenthal, {David I.} and Fuller, {Clifton D.} and Gunn, {Gary B.} and Frank, {Steven J.} and Morrison, {William H.} and Shah, {Shalin J.} and Anna Lee and Spiotto, {Michael T.} and Su, {Shirley Y.} and Renata Ferrarotto and Jack Phan",
note = "Funding Information: Dr. Ferrarotto serves on the advisory board for Ayala and Sanofi‐Regeneron, reports consulting fees from Celestia, and honorarium from Research Cancer Institute, all unrelated to this project. Dr. Frank reports receiving fees as a consultant and advisory board member of Varian, as a director and founder of C4 Imaging, as an advisor for Hitachi, as honoraria from Boston Scientific, and as a member of the board of directors of the National Comprehensive Cancer Center (NCCN), all unrelated to this project. Dr. Frank also sits on the scientific advisory board for Breakthrough Chronic Care and has research grants from C4 Imaging, Eli Lilly, Elekta, and Hitachi. Dr. Fuller has received direct industry grant support, honoraria, and travel funding from Elekta unrelated to this project. Dr. Phan serves on the scientific advisory board for Cyberknife for Accuray, Inc. Funding Information: The M. D. Anderson Cancer Center, Grant/Award Numbers: P30CA016672, P30CA016672‐44; NIH/NIDCR, Grant/Award Number: R01DE027445; National Science Foundation, Grant/Award Number: NSF 1933369; NIH/NCI Cancer Center, Grant/Award Number: P30CA016672; National Cancer Institute, Grant/Award Number: 1R01CA218148; NIDCR, Grant/Award Number: R01DE028290; National Institutes of Health (NIH), Grant/Award Number: R25EB025787‐01 Funding information Funding Information: Dr. Fuller received/receives funding and salary support during the period of study execution from: the National Institutes of Health (NIH) NIBIB Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787‐01); NIDCR Academic Industrial Partnership Grant (R01DE028290); NCI Early Phase Clinical Trials in Imaging and Image‐Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from The UT M. D. Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); and an NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). Dr. Spiotto receives funding from the NIH/NIDCR (R01DE027445). Direct infrastructure support is provided by the multidisciplinary Radiation Oncology/Cancer Imaging Program (P30CA016672‐44) of The M. D. Anderson Cancer Center Support Grant (P30CA016672) and The M. D. Anderson Program in Image‐guided Cancer Therapy. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",
year = "2021",
month = nov,
doi = "10.1002/hed.26820",
language = "English (US)",
volume = "43",
pages = "3331--3344",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "11",
}